JNJ

225.54

-0.03%↓

UNH

370.35

+1.35%↑

TMO

465.79

-0.01%↓

ISRG

450.79

-1.5%↓

ABT

86.59

-2.53%↓

JNJ

225.54

-0.03%↓

UNH

370.35

+1.35%↑

TMO

465.79

-0.01%↓

ISRG

450.79

-1.5%↓

ABT

86.59

-2.53%↓

JNJ

225.54

-0.03%↓

UNH

370.35

+1.35%↑

TMO

465.79

-0.01%↓

ISRG

450.79

-1.5%↓

ABT

86.59

-2.53%↓

JNJ

225.54

-0.03%↓

UNH

370.35

+1.35%↑

TMO

465.79

-0.01%↓

ISRG

450.79

-1.5%↓

ABT

86.59

-2.53%↓

JNJ

225.54

-0.03%↓

UNH

370.35

+1.35%↑

TMO

465.79

-0.01%↓

ISRG

450.79

-1.5%↓

ABT

86.59

-2.53%↓

Strona główna・Stock List・Puma Biotechnology Inc
Search

Puma Biotechnology Inc

Open

SectorHealthcare

7.44 -0.67

Neutral

Price update 1 maj 2026, 19:59 UTC

BuySell

Overview

Share price change

24h

Current

Min

7.44

Max

7.5

Key metrics

By Trading Economics

Income

3M

12M

Sales

21M

76M

P/E

Sector Avg

12.312

67.147

Profit margin

15.633

Employees

179

EBITDA

13M

27M

Recommendations

By TipRanks

Recommendations

Neutral

12 Months Forecast

-33.24% downside

Dividends

By Dow Jones

Next Earnings

7 maj 2026

Market Stats

By TradingEconomics

Market Cap

24M

382M

Previous open

8.11

Previous close

7.44

News Sentiment

By Acuity

50%

50%

176 / 347 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

3.07 / 3.075 Support & Resistance

Puma Biotechnology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 maj 2026, 22:17 UTC

Earnings

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

DJ

Read

4 maj 2026, 23:47 UTC

Earnings

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

DJ

Read

4 maj 2026, 23:45 UTC

Earnings

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

DJ

Read

4 maj 2026, 23:45 UTC

Earnings

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

DJ

Read

4 maj 2026, 23:40 UTC

Market Talk

Gold Steady Amid Likely Technical Recovery -- Market Talk

DJ

Read

4 maj 2026, 22:44 UTC

Acquisitions, Mergers, Takeovers

Regis: Jim Beyer To Be Chief Executive of Combined Company

DJ

Read

4 maj 2026, 22:43 UTC

Acquisitions, Mergers, Takeovers

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

DJ

Read

4 maj 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

DJ

Read

4 maj 2026, 22:42 UTC

Acquisitions, Mergers, Takeovers

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

DJ

Read

4 maj 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

DJ

Read

4 maj 2026, 22:41 UTC

Acquisitions, Mergers, Takeovers

Regis: Pro Forma Market Capitalization About A$10.7 Billion

DJ

Read

4 maj 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Shareholders to Own About 51% of Combined Company

DJ

Read

4 maj 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Board Unanimously Endorsed, Supported Deal

DJ

Read

4 maj 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Regis: Deal Unanimously Recommended by Vault Board

DJ

Read

4 maj 2026, 22:39 UTC

Acquisitions, Mergers, Takeovers

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

DJ

Read

4 maj 2026, 22:38 UTC

Acquisitions, Mergers, Takeovers

Regis Resources to Acquire All Ordinary Shares in Vault

DJ

Read

4 maj 2026, 22:38 UTC

Acquisitions, Mergers, Takeovers

Regis Resources, Vault Minerals Agree to Merger of Equals

DJ

Read

4 maj 2026, 22:37 UTC

Earnings
Acquisitions, Mergers, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

DJ

Read

4 maj 2026, 22:26 UTC

Earnings
Acquisitions, Mergers, Takeovers

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

DJ

Read

4 maj 2026, 22:02 UTC

Earnings

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

DJ

Read

4 maj 2026, 22:00 UTC

Market Talk

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

DJ

Read

4 maj 2026, 21:52 UTC

Earnings

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

DJ

Read

4 maj 2026, 21:50 UTC

Earnings

Westpac: Some Sectors More Affected Than Others>WBC.AU

DJ

Read

4 maj 2026, 21:50 UTC

Earnings

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

DJ

Read

4 maj 2026, 21:49 UTC

Earnings

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

DJ

Read

4 maj 2026, 21:44 UTC

Earnings

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

DJ

Read

4 maj 2026, 21:44 UTC

Earnings

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

DJ

Read

4 maj 2026, 21:43 UTC

Earnings

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

DJ

Read

4 maj 2026, 21:41 UTC

Earnings

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

DJ

Read

4 maj 2026, 21:40 UTC

Earnings

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

DJ

Read

Peer Comparison

Price change

Puma Biotechnology Inc Forecast

Price Target

By TipRanks

-33.24% downside

12 Months Forecast

Average 5 USD  -33.24%

High 5 USD

Low 5 USD

Based on 1 Wall Street analysts offering 12 month price targets forPuma Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

0

Buy

1

Hold

0

Sell

Based on 1 analysts giving stock ratings to Puma Biotechnology Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.07 / 3.075Support & Resistance

Short Term

Weak Bullish Evidence

Recent bullish events outweigh bearish events.

Intermediate Term

Weak Bullish Evidence

Recent bullish events outweigh bearish events.

Long Term

Bullish Evidence

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

176 / 347 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Other stocks from the sector

JNJ

Johnson and Johnson

225.54

↓-0.03%

UNH

UnitedHealth Group Inc

370.35

↑ +1.35%

TMO

Thermo Fisher Scientific Inc

465.79

↓-0.01%

ISRG

Intuitive Surgical Inc

450.79

↓-1.5%

ABT

Abbott Laboratories

86.59

↓-2.53%
help-icon Live chat